T. Rowe Price Associates
USPH icon

T. Rowe Price Associates’s US Physical Therapy USPH Stock Holding History

T. Rowe Price Associates’s Portfolio USPH Stock Details USPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
15,856
+2,732
+21% +$224K ﹤0.01% 2070
2025
Q4 		$1.02M Buy
13,124
+1,192
+10% +$96.7K ﹤0.01% 2075
2025
Q3 		$1.01M Buy
11,932
+699
+6% +$56K ﹤0.01% 2062
2025
Q2 		$879K Buy
11,233
+941
+9% +$69.4K ﹤0.01% 2043
2025
Q1 		$745K Buy
10,292
+988
+11% +$82.9K ﹤0.01% 2090
2024
Q4 		$826K Sell
9,304
-5,333
-36% -$475K ﹤0.01% 2054
2024
Q3 		$1.24M Buy
14,637
+139
+1% +$12.3K ﹤0.01% 1881
2024
Q2 		$1.34M Sell
14,498
-3,242
-18% -$328K ﹤0.01% 1758
2024
Q1 		$2M Sell
17,740
-3,072
-15% -$307K ﹤0.01% 1564
2023
Q4 		$1.94M Sell
20,812
-5,201
-20% -$458K ﹤0.01% 1551
2023
Q3 		$2.39M Sell
26,013
-444
-2% -$47.7K ﹤0.01% 1392
2023
Q2 		$3.21M Buy
26,457
+347
+1% +$37.4K ﹤0.01% 1324
2023
Q1 		$2.56M Sell
26,110
-2,998
-10% -$286K ﹤0.01% 1382
2022
Q4 		$2.36M Sell
29,108
-235,148
-89% -$19.7M ﹤0.01% 1407
2022
Q3 		$20.1M Sell
264,256
-979,641
-79% -$94.2M ﹤0.01% 902
2022
Q2 		$136M Buy
1,243,897
+1,260
+0.1% +$134K 0.02% 577
2022
Q1 		$124M Buy
1,242,637
+3,605
+0.3% +$344K 0.01% 663
2021
Q4 		$118M Sell
1,239,032
-47,541
-4% -$4.77M 0.01% 712
2021
Q3 		$142M Sell
1,286,573
-1,488
-0.1% -$170K 0.01% 657
2021
Q2 		$149M Sell
1,288,061
-12,826
-1% -$1.47M 0.01% 651
2021
Q1 		$135M Sell
1,300,887
-13,417
-1% -$1.67M 0.01% 678
2020
Q4 		$158M Buy
1,314,304
+30,556
+2% +$3.08M 0.02% 588
2020
Q3 		$112M Buy
1,283,748
+27,254
+2% +$2.34M 0.01% 624
2020
Q2 		$102M Buy
1,256,494
+58,426
+5% +$4.26M 0.01% 635
2020
Q1 		$82.7M Buy
1,198,068
+201,138
+20% +$21.2M 0.01% 628
2019
Q4 		$114M Buy
996,930
+18,095
+2% +$2.25M 0.01% 627
2019
Q3 		$128M Sell
978,835
-75,478
-7% -$9.83M 0.02% 549
2019
Q2 		$129M Buy
1,054,313
+263
+0% +$30.2K 0.02% 579
2019
Q1 		$111M Sell
1,054,050
-12,253
-1% -$1.32M 0.02% 610
2018
Q4 		$109M Sell
1,066,303
-53,650
-5% -$5.96M 0.02% 583
2018
Q3 		$133M Sell
1,119,953
-136,209
-11% -$15.4M 0.02% 592
2018
Q2 		$121M Buy
1,256,162
+5,439
+0.4% +$504K 0.02% 609
2018
Q1 		$102M Buy
1,250,723
+27,990
+2% +$2.17M 0.02% 645
2017
Q4 		$88.3M Sell
1,222,733
-16,182
-1% -$1.1M 0.01% 688
2017
Q3 		$76.1M Buy
1,238,915
+26,072
+2% +$1.59M 0.01% 707
2017
Q2 		$73.3M Buy
1,212,843
+46,659
+4% +$2.98M 0.01% 698
2017
Q1 		$76.2M Buy
1,166,184
+144,969
+14% +$10.3M 0.01% 668
2016
Q4 		$71.7M Buy
1,021,215
+711,430
+230% +$45.2M 0.01% 690
2016
Q3 		$19.4M Buy
309,785
+28,455
+10% +$1.75M ﹤0.01% 1142
2016
Q2 		$16.9M Buy
281,330
+12,300
+5% +$674K ﹤0.01% 1152
2016
Q1 		$13.4M Buy
269,030
+10,100
+4% +$502K ﹤0.01% 1200
2015
Q4 		$13.9M Buy
258,930
+30,630
+13% +$1.53M ﹤0.01% 1197
2015
Q3 		$10.2M Buy
228,300
+90,500
+66% +$4.51M ﹤0.01% 1302
2015
Q2 		$7.55M Buy
137,800
+131,400
+2,053% +$6.51M ﹤0.01% 1409
2015
Q1 		$304K Hold
6,400
– – ﹤0.01% 2181
2014
Q4 		$269K Buy
+6,400
New +$252K ﹤0.01% 2222

Other funds holding USPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bahl & Gaynor Cincinnati, Ohio $19.8B AUM 19.53% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SAM
Southernsun Asset Management Memphis, Tennessee $690M AUM 30.68% 1-Year Est. Return

T. Rowe Price Associates's USPH Position: Q1 2026 in Review

T. Rowe Price Associates increased its US Physical Therapy (USPH) stake by 21% in Q1 2026, buying an estimated $224K and bringing the position to 15,856 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

T. Rowe Price Associates first reported a position in USPH in Q4 2014 and has held it in 46 quarters since. The position peaked at $158M in Q4 2020. 229 funds tracked by Wall St. Rank hold USPH as of Q1 2026.

  • T. Rowe Price Associates held 15,856 shares of US Physical Therapy worth $1.19M as of Q1 2026.
  • T. Rowe Price Associates bought 2,732 US Physical Therapy shares in Q1 2026, an estimated $224K.
  • US Physical Therapy made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2070 holding.
  • T. Rowe Price Associates first reported a position in US Physical Therapy in Q4 2014 and has held it in 46 quarters since.
  • T. Rowe Price Associates's US Physical Therapy position peaked at $158M in Q4 2020.
  • 229 funds tracked by Wall St. Rank held US Physical Therapy as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.